Closing

1D

YTD

Market cap

-

52 week high

-

52 week low

-

Volume

-

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

-

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

-

Operating Margin

-

Beta

-

Revenue Growth (Annual)

-

52 week high

-

52 week low

-

Div. Yield

-

EPS Annual Growth

-

* Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Biostage, Inc. is a clinical-stage biotechnology company. The Company is focused on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects. The Company’s Biostage Organ-Regeneration technology uses the patient’s own stem cells seeded on a temporary scaffold to regrow and restore their damaged organ. Its lead product candidate includes Biostage Esophageal Implant, for the treatment of severe esophageal disease which is in a phase I/II clinical trial. Its esophageal implant consists of a hollow, tubular scaffold consisting of a thin polyurethane fiber mesh that is formed in the shape of the damaged section of the organ. This scaffold is seeded with the patient’s own mesenchymal stem cells which are obtained a few weeks before surgery through a biopsy of adipose (fat) tissue from the patient’s abdomen. The stem cells are isolated and expanded and then seeded onto the tubular scaffold.